Considering Synairgen’s upcoming Phase III readout of SNG001 for the treatment of hospitalised patients with moderate COVID-19, we assess the prospects for SNG001, re-visit our valuation and assess the outlook for subsequent value appreciation. Positive Phase III data will not only open the opportunity for a much-needed COVID-19 drug therapy for hospitalised patients, given the high number of patients still being admitted to hospitals, but will potentially open the prospect of future pandemic pr ....
06 Jan 2022
Synairgen - Phase III data in early 2022 – transformational event
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Synairgen - Phase III data in early 2022 – transformational event
Synairgen plc (SNG:LON) | 5.9 0 4.8% | Mkt Cap: 11.9m
- Published:
06 Jan 2022 -
Author:
Mark Brewer | Cavendish Research -
Pages:
17
Considering Synairgen’s upcoming Phase III readout of SNG001 for the treatment of hospitalised patients with moderate COVID-19, we assess the prospects for SNG001, re-visit our valuation and assess the outlook for subsequent value appreciation. Positive Phase III data will not only open the opportunity for a much-needed COVID-19 drug therapy for hospitalised patients, given the high number of patients still being admitted to hospitals, but will potentially open the prospect of future pandemic pr ....